Arm A: ABC+3TC+NNRTI — Competitive Intelligence Brief

Arm A: ABC+3TC+NNRTI (Arm A: ABC+3TC+NNRTI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (nucleoside reverse transcriptase inhibitors + non-nucleoside reverse transcriptase inhibitor). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (nucleoside reverse transcriptase inhibitors + non-nucleoside reverse transcriptase inhibitor) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Arm A: ABC+3TC+NNRTI (Arm A: ABC+3TC+NNRTI) — Medical Research Council. This combination inhibits HIV reverse transcriptase through two nucleoside analogs (ABC and 3TC) and one non-nucleoside reverse transcriptase inhibitor (NNRTI), blocking viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Arm A: ABC+3TC+NNRTI TARGET	Arm A: ABC+3TC+NNRTI	Medical Research Council	marketed	Antiretroviral combination therapy (nucleoside reverse transcriptase inhibitors + non-nucleoside reverse transcriptase inhibitor)	HIV reverse transcriptase
Lamiduvine (Epivir)	Lamiduvine (Epivir)	Catholic University of the Sacred Heart	marketed	Nucleoside Reverse Transcriptase Inhibitor (NRTI)	HIV reverse transcriptase
Abacavir/Lamivudine	Abacavir/Lamivudine	GlaxoSmithKline	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
Abacavir/lamivudine/zidovudine	Abacavir/lamivudine/zidovudine	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Atazanavir/ Stavidine / Lamivudine	Atazanavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Emtricitabine / Tenofovir	Emtricitabine / Tenofovir	The Miriam Hospital	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV reverse transcriptase
DOR/3TC/TDF	DOR/3TC/TDF	Prism Health North Texas	marketed	Antiretroviral combination therapy (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (nucleoside reverse transcriptase inhibitors + non-nucleoside reverse transcriptase inhibitor) class)

1. Medical Research Council · 1 drug in this class